July 29, 2010 – To help physicians overcome the medical technology challenges that impede rapid adoption of connected medical technologies, Best Buy For Business and Cardiac Science Corp. recently announced an alliance.

July 28, 2010 – The Council on Radionuclides and Radiopharmaceuticals (CORAR) applauded a recent decision by a Medicare administrative to correct coding, coverage and payment policies for radiopharmaceuticals used with myocardial perfusion imaging procedures.

July 28, 2010 – This week St. Jude Medical filed a patent infringement lawsuit against Volcano Corp. over its fractional flow reserve (FFR) wires. The suit was filed in federal district court in Delaware. Volcano said the claims against it are entirely without merit.

July 27, 2010 – Two new cardiac stress test systems optimize space to allow testing in a greater variety of settings, offer wireless data acquisition and better electronic medical record (EMR) connectivity.


Heart failure is a progressively debilitating disease that dramatically decreases the life expectancy and quality of life of affected patients. Nearly 5.8 million Americans are diagnosed with heart failure today, according to annual American Heart Association statistics.

July 27, 2010 – Atherosclerotic plaque causes audible turbulence in the bloodstream and a new device can help isolate these sounds to aid in earlier detection of plaque changes.

July 27, 2010 – Results of the largest U.S. outpatient heart failure clinical study show that implementation of a process improvement program significantly improved adherence to evidence-based, guideline-recommended cardiac resynchronization therapy (CRT), implantable cardioverter-defibrillator (ICD) and drug therapy.

July 26, 2010 – Today a fourth-generation intracranial aneurysm stent
system was released in both the U.S. and European markets. Boston Scientific’s Neuroform EZ Stent System is designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms.

July 26, 2010 – The U.S. Food and Drug Administration (FDA) approved the first generic version of Lovenox (enoxaparin sodium injection), an anticoagulant drug used for multiple indications, including prevention of deep vein thrombosis (DVT), a potentially deadly blood clotting condition.

July 26, 2010 – A new three-in-one combination drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension in patients who do not respond to dual medical treatment. Daiichi Sankyo Inc.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now